Logo

EYPT

EyePoint Pharmaceuticals, Inc.

EYPT

EyePoint Pharmaceuticals, Inc. • NASDAQ
$14.83 ▲ 0.27% (+0.04)
Market Cap $1.02 B
52w High $14.96
52w Low $3.91
Dividend Yield 0%
P/E -4.94
Volume 249.51K
Outstanding Shares 68.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $966K ▼ $62.27M ▼ $-59.732M ▼ -6.183K% ▼ $-0.85 $-59.156M ▲
Q2-2025 $5.333M ▼ $67.395M ▼ $-59.426M ▼ -1.114K% ▼ $-0.85 ▼ $-61.689M ▼
Q1-2025 $24.453M ▲ $72.485M ▲ $-45.195M ▼ -184.824% ▲ $-0.65 ▼ $-48.34M ▼
Q4-2024 $11.588M ▲ $56.011M ▲ $-41.399M ▼ -357.258% ▼ $-0.64 ▼ $-40.828M ▼
Q3-2024 $10.524M $42.536M $-29.361M -278.991% $-0.54 $-28.953M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $204.022M ▼ $251.695M ▼ $51.513M ▼ $200.182M ▼
Q2-2025 $255.733M ▼ $301.147M ▼ $55.138M ▼ $246.009M ▼
Q1-2025 $318.194M ▼ $362.564M ▼ $64.168M ▼ $298.396M ▼
Q4-2024 $370.913M ▲ $418.465M ▲ $81.964M ▼ $336.501M ▲
Q3-2024 $253.793M $300.917M $82.183M $218.734M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-59.732M ▼ $-59.354M ▲ $55.385M ▲ $7.403M ▲ $3.434M ▲ $-60.152M ▲
Q2-2025 $-59.426M ▼ $-62.589M ▼ $48.336M ▲ $238K ▲ $-14.015M ▲ $-63.809M ▼
Q1-2025 $-45.195M ▼ $-53.12M ▼ $39.525M ▲ $-951K ▼ $-14.546M ▼ $-53.396M ▼
Q4-2024 $-41.399M ▼ $-35.849M ▲ $-95.962M ▼ $151.685M ▲ $19.874M ▲ $-36.233M ▲
Q3-2024 $-29.361M $-39.028M $16.196M $11.893M $-10.939M $-40.602M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License And Collaboration Agreement
License And Collaboration Agreement
 $20.00M ▲$10.00M ▼$10.00M ▲$0 ▼
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Royalty
Royalty
 $0 ▲$10.00M ▲$0 ▼$0 ▲
Y U T I Q Product
Y U T I Q Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement EyePoint is still very much a development‑stage biotech from a financial standpoint. Revenue has stayed very small and fairly flat over the last several years, showing that current products and partnerships are not yet driving meaningful commercial scale. The company does generate healthy gross margins on what it sells, but research, clinical work, and overhead spending are far larger than its revenue. As a result, operating losses have been consistent every year and widened in the most recent period as the company stepped up investment in its pipeline. Net losses and per‑share losses remain significant, which is typical for a small biotech focused on late‑stage clinical programs rather than mature product sales.

Balance Sheet

Balance Sheet The balance sheet has strengthened over the last five years, with total assets and shareholders’ equity increasing meaningfully. This suggests the company has raised capital to fund its development work rather than relying on profits from operations. Cash levels were built up sharply in the recent past and then drawn down in the latest year, but still sit comfortably above earlier years, providing some financial cushion. Debt is modest and has come down, so the company is not heavily leveraged. Overall, EyePoint has a much sturdier equity base than it did a few years ago, but it remains dependent on external funding as long as it is loss‑making.

Cash Flow

Cash Flow Cash flow patterns confirm the early‑stage biotech profile. The business has generally consumed cash in its core operations, with a brief period where cash use nearly flattened before turning more negative again in the latest year as clinical and development spending increased. Free cash flow closely tracks operating cash flow because capital spending is minimal; the company is not building factories, it is funding trials and R&D. This means EyePoint’s cash runway and its ability to keep raising money are key financial variables to watch, since the business is not yet self‑funding.

Competitive Edge

Competitive Edge EyePoint operates in a focused niche: long‑acting treatments for serious eye diseases. Its main edge comes from proprietary drug‑delivery implants that can release medicine inside the eye for many months or even years, which can be far more convenient than frequent injections or eye drops. The technology is already validated in several FDA‑approved products, giving the company credibility and a higher barrier to entry for would‑be rivals. At the same time, EyePoint is small and competes against large eye‑care and biotech companies in conditions like wet age‑related macular degeneration and diabetic eye disease, where competition is intense and well‑funded. Its commercial products have not yet broken out as blockbuster successes, so its long‑term competitive strength depends heavily on whether its next‑generation programs can secure strong clinical data, regulatory approvals, and commercial partners.

Innovation and R&D

Innovation and R&D Innovation is the core of EyePoint’s story. The company has built two sustained‑release platforms, Durasert and Verisome, and an updated bioerodible version (Durasert E) that dissolves over time so it does not need to be removed. These platforms underpin existing products like YUTIQ and DEXYCU and are being used to develop new treatments for major retinal diseases. The lead program, DURAVYU (EYP‑1901), aims to treat conditions such as wet macular degeneration and diabetic eye disease with injections that may be needed only every six months, which would be a major convenience upgrade if the data remain strong. Additional pipeline work, including EYP‑2301 and potential expansion into other serious eye conditions, shows a platform approach rather than a single‑drug bet. However, as with all biotech R&D, there is significant clinical, regulatory, and timing uncertainty, and outcomes for key trials will be pivotal for the company’s future.

Summary

EyePoint Pharmaceuticals is a science‑driven eye‑disease specialist with validated drug‑delivery technology, small but steady current revenue, and a clear focus on building value through its pipeline rather than its existing product base. Financially, the company has strengthened its balance sheet over time but continues to post sizable operating and net losses and to use cash in its operations, which is typical for a company at this stage. Strategically, its sustained‑release platforms and experience in retinal disease provide a credible niche advantage, yet it operates in highly competitive markets dominated by much larger players. The company’s long‑term outlook hinges largely on the success of DURAVYU and other pipeline candidates, the ability to secure and manage strong partnerships, and continued access to capital while it remains unprofitable. Overall, it is a classic high‑risk, high‑uncertainty biotech profile with meaningful scientific upside but dependence on future trial, regulatory, and commercial milestones.

NEWS

November 19, 2025 · 7:00 AM UTC

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Read more

November 17, 2025 · 7:00 AM UTC

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more

November 5, 2025 · 7:00 AM UTC

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Read more

November 3, 2025 · 7:00 AM UTC

EyePoint Announces Participation at Upcoming Investor Conferences

Read more

October 29, 2025 · 7:00 AM UTC

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Read more